A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.
Status:
Completed
Trial end date:
2000-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and tolerability of ZDV when given to
premature infants born to HIV-positive women to prevent HIV infection.
ZDV has been used successfully to prevent the transmission of HIV from mother to child during
pregnancy and birth. However, ZDV has been given to very few premature babies, and the best
dose to use has not yet been determined.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)